Skip to main content
Premium Trial:

Request an Annual Quote

Gene Security Network Raises $20M, Renames Itself Natera

NEW YORK (GenomeWeb News) – Gene Security Network today announced it has completed a $20 million financing round and changed its name to Natera.

The funds will go toward development and commercialization of the company's non-invasive prenatal diagnostic test for Down syndrome and other genetic ailments. A clinical trial funded by the National Institutes of Health for the prenatal test also will be expanded with a launch of the test anticipated sometime this year.

Its test uses bioinformatics technology to deliver results from quantities of DNA as small as that from a single cell, it said.

Lightspeed Venture Partners led the round and were joined by existing investors Claremont Creek Ventures and Sequoia Capital.

Natera, based in Redwood City, Calif., raised $4 million in a Series A round in 2007 and $6 million and $12 million in subsequent rounds.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.